SPS
Susquehanna Portfolio Strategies Portfolio holdings
AUM
$4.58B
This Quarter Return
+9.25%
1 Year Return
+20.83%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.58B
AUM Growth
+$4.58B
(+1,869%)
Cap. Flow
+$4.34B
Cap. Flow
% of AUM
94.76%
Top 10 Holdings %
Top 10 Hldgs %
12.71%
Holding
855
New
695
Increased
118
Reduced
12
Closed
24
Top Buys
| 1 |
Oracle
ORCL
|
$70.8M |
| 2 |
Pfizer
PFE
|
$66M |
| 3 |
Merck
MRK
|
$63.4M |
| 4 |
Blackrock
BLK
|
$59.6M |
| 5 |
Amazon
AMZN
|
$57.8M |
Top Sells
| 1 |
Manulife Financial
MFC
|
$8.18M |
| 2 |
PG&E
PCG
|
$4.62M |
| 3 |
Blackstone
BX
|
$3.1M |
| 4 |
JWN
Nordstrom
JWN
|
$2.04M |
| 5 |
Albertsons Companies
ACI
|
$1.94M |
Sector Composition
| 1 | Technology | 17.5% |
| 2 | Financials | 16.1% |
| 3 | Healthcare | 13.62% |
| 4 | Consumer Discretionary | 13.01% |
| 5 | Industrials | 11.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
801
Dana Inc
DAN
$2.64B
| $185K | ﹤0.01% |
+10,778
| New | +$185K |
|
802
Rayonier Advanced Materials
RYAM
$373M
| $184K | ﹤0.01% |
+47,748
| New | +$184K |
|
803
C4 Therapeutics
CCCC
$185M
| $181K | ﹤0.01% |
+126,900
| New | +$181K |
|
804
Sportsman's Warehouse
SPWH
$103M
| $174K | ﹤0.01% |
+50,455
| New | +$174K |
|
805
Spire Global
SPIR
$281M
| $169K | ﹤0.01% |
+14,176
| New | +$169K |
|
806
Allot
ALLT
$362M
| $160K | ﹤0.01% |
+18,753
| New | +$160K |
|
807
SGHC Ltd
SGHC
$5.88B
| $159K | ﹤0.01% |
+14,500
| New | +$159K |
|
|
VERV
808
DELISTED
Verve Therapeutics
VERV
| $149K | ﹤0.01% |
+13,300
| New | +$149K |
|
809
Black Diamond Therapeutics
BDTX
$157M
| $142K | ﹤0.01% |
+57,143
| New | +$142K |
|
810
Pulmonx
LUNG
$69.7M
| $139K | ﹤0.01% |
+53,526
| New | +$139K |
|
811
EVgo
EVGO
$521M
| $131K | ﹤0.01% |
+35,883
| New | +$131K |
|
812
Provident Bancorp
PVBC
$229M
| $127K | ﹤0.01% |
+10,155
| New | +$127K |
|
|
BORR
813
Borr Drilling
BORR
$833M
| $124K | ﹤0.01% |
+68,030
| New | +$124K |
|
814
Ribbon Communications
RBBN
$722M
| $121K | ﹤0.01% |
+30,173
| New | +$121K |
|
815
ADC Therapeutics
ADCT
$345M
| $116K | ﹤0.01% |
+43,426
| New | +$116K |
|
816
Arteris
AIP
$402M
| $112K | ﹤0.01% |
+11,775
| New | +$112K |
|
817
Gold Royalty Corp
GROY
$618M
| $111K | ﹤0.01% |
+50,203
| New | +$111K |
|
818
Luminar Technologies
LAZR
$117M
| $97.4K | ﹤0.01% |
+33,937
| New | +$97.4K |
|
819
Astria Therapeutics
ATXS
$349M
| $95.9K | ﹤0.01% |
+17,900
| New | +$95.9K |
|
820
Organogenesis Holdings
ORGO
$653M
| $92.6K | ﹤0.01% |
+25,294
| New | +$92.6K |
|
821
Douglas Elliman
DOUG
$241M
| $91.9K | ﹤0.01% |
+39,603
| New | +$91.9K |
|
822
Savara
SVRA
$567M
| $90.8K | ﹤0.01% |
+39,839
| New | +$90.8K |
|
823
Lexeo Therapeutics
LXEO
$259M
| $89.5K | ﹤0.01% |
+22,259
| New | +$89.5K |
|
824
NGL Energy Partners
NGL
$692M
| $84.6K | ﹤0.01% |
+19,813
| New | +$84.6K |
|
|
RERE
825
ATRenew
RERE
$1.05B
| $83.9K | ﹤0.01% |
+25,346
| New | +$83.9K |
|